Patients may not have received any other investigational agents within 4 weeks of study entry
Have received any investigational new drug within the past 30 days or planning to receive such during the study period
Patients may not be planning to receive any other investigational agents
Participants who received investigational agents, other than investigational antiretroviral agents for HIV, within the 4 weeks before randomization, unless approved by the study chair
Patients who are receiving any other investigational agents or who have received pomalidomide in the past
Participants who received any other chronic (defined as more than 50% of the time in the last 6 months) systemic immunomodulatory agents (replacement doses of steroids for adrenal insufficiency are permitted or treatment with prednisone =< 5 mg/day); receipt of investigational agents within the 4 weeks before randomization enrollment, other than investigational antiretroviral agents for HIV and investigational or approved agents for hepatitis C, are also exclusionary
Concurrent administration of any other investigational agents
Patients must not receive any other investigational agents while on study or within four weeks prior to registration
Participants who are receiving any other investigational agents within 4 weeks prior to enrollment; investigational antiretroviral agents for HIV are acceptable
Patients must not be planning to receive any other investigational agents during the course of protocol treatment
Patients must not receive any other investigational agents while on study or within four weeks prior to randomization
Use of any investigational product within 4 weeks prior to randomization
Patients may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeks
Any other investigational agents within the past 4 weeks
Patients should not have received any other investigational agents within the past 4 weeks
Patients who are receiving any other investigational agents; all investigational agents other than ibrutinib must have been discontinued at least 4 weeks prior to beginning treatment; prior ibrutinib therapy must have been discontinued at least 2 weeks prior to beginning therapy
Patients must not be receiving or planning to receive any other investigational agents
Concurrent anticancer therapy (including other investigational agents)
Concomitant therapy with any anticancer agents, immunosuppressive agents, other investigational anticancer therapies
Patients must not have received radiation therapy, non-cytotoxic agents or investigational agents or systemic corticosteroids within 14 days prior to registration
Participants should not have received any other investigational agents nor have participated in an investigational trial within the past 4 weeks